American Renal Associates Holdings’ (NYSE:ARA) lock-up period will expire on Tuesday, October 18th. American Renal Associates Holdings had issued 7,500,000 shares in its IPO on April 21st. The total size of the offering was $165,000,000 based on an initial share price of $22.00. After the end of the company’s lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

ARA has been the topic of several research analyst reports. Zacks Investment Research downgraded shares of American Renal Associates Holdings from a “buy” rating to a “hold” rating in a report on Tuesday, July 26th. Wells Fargo & Co. restated a “buy” rating on shares of American Renal Associates Holdings in a report on Sunday, September 25th. Barclays PLC restated a “buy” rating and set a $31.00 target price on shares of American Renal Associates Holdings in a report on Thursday, August 18th. Bank of America Corp. restated a “buy” rating and set a $35.00 target price on shares of American Renal Associates Holdings in a report on Monday, August 22nd. Finally, Leerink Swann reaffirmed an “outperform” rating on shares of American Renal Associates Holdings in a research note on Sunday, August 21st. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $31.17.

American Renal Associates Holdings (NYSE:ARA) opened at 17.91 on Tuesday. The company’s market capitalization is $552.85 million. American Renal Associates Holdings has a 52 week low of $17.54 and a 52 week high of $29.65. The stock’s 50 day moving average is $19.67 and its 200 day moving average is $24.49.

American Renal Associates Holdings (NYSE:ARA) last announced its earnings results on Tuesday, August 9th. The company reported ($0.75) EPS for the quarter. The company earned $185.60 million during the quarter, compared to analyst estimates of $161.50 million. Analysts predict that American Renal Associates Holdings will post $0.95 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in ARA. Acrospire Investment Management LLC bought a new stake in shares of American Renal Associates Holdings during the second quarter valued at approximately $130,000. American International Group Inc. bought a new stake in shares of American Renal Associates Holdings during the second quarter valued at approximately $146,000. Nationwide Fund Advisors bought a new stake in shares of American Renal Associates Holdings during the second quarter valued at approximately $166,000. Rhumbline Advisers bought a new stake in shares of American Renal Associates Holdings during the second quarter valued at approximately $225,000. Finally, Alambic Investment Management L.P. bought a new stake in shares of American Renal Associates Holdings during the second quarter valued at approximately $229,000. Institutional investors and hedge funds own 85.20% of the company’s stock.

About American Renal Associates Holdings

American Renal Associates Holdings, Inc is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD).

5 Day Chart for NYSE:ARA

Receive News & Stock Ratings for American Renal Associates Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc. and related stocks with our FREE daily email newsletter.